Ofer Shina is 38 and carries a gene that brings on Alzheimer's disease early. His father began losing his memory at 40, and an uncle later developed the same symptoms. Genetic testing eventually found the cause: an aggressive mutation in a gene called PSEN1 that runs through about half of his father's side of the family. Shina was tested after his father died. "For me, knowing is more important," he said. "Putting a light on it is better." Shina, a product manager with 13 years in the tech industry and no training in biology, went looking for a treatment in the scientific literature. "I taught myself to read a paper every day before I start the day," he told The Media Line. He says he looked at more than 200 possible approaches and thousands of papers. Most of the work he found was aimed at amyloid, the protein that has been the target of hundreds of failed Alzheimer's trials. Then he found the work of Prof. Varda Shoshan-Barmatz at Ben-Gurion University of the Negev. Shina is co-founder and chief operating officer of X-tosis, Inc., a biotech startup based in Gainesville, Florida, and built on Shoshan-Barmatz's research. The Michael J. Fox Foundation for Parkinson's Research awarded the company a $2.74 million grant, announced in June, to move its lead drug toward…
Israeli man facing early-onset Alzheimer's develops potential treatment for Parkinson's disease
Initially turned away, Ofer Shina built X-tosis around Prof. Varda Shoshan-Barmatz's research. The startup has a $2.74 million Michael J. Fox Foundation grant and is initially targeting Parkinson's.
In brief
Ofer Shina is 38 and carries a gene that brings on Alzheimer's disease early. Shina was tested after his father died. Varda Shoshan-Barmatz at Ben-Gurion University of the Negev. Shina is co-founder and chief operating officer of X-tosis, Inc., a biotech startup based in Gainesville, Florida, and built on Shoshan-Barmatz's research.
This is the opening of the story, shared with credit to The Jerusalem Post. The rest of the report — with every detail — continues on the publisher’s website.
Continue reading at The Jerusalem Post ↗



